Page 419 - An Evidence Review of Active Surveillance in Men With Localized Prostate Cancer

Appendix Table C3.2. KQ3 multivariable analyses (continued)
Author Factors Data source Duration Analyzed Population WW/AS Methods Results as described in paper
yr sample characteristics definitions
PMI
Sadetsky 163 Delivery CaPSURE 1995- 2507 Newly Not Multinomial Using RP as the baseline:
2008 system 2006 diagnosed explicitly logistic Insurance status, insurance
17893700 localized provided regression provider for predicting EM,
prostate EM vs. EBRT - HMO vs. not, OR=0.62 (CI 0.29,
cancer, >65 yr. vs. ADT vs. 1.33)
BT vs. RP - PPO vs. not, OR=0.95 (CI 0.36,
2.51)
- VA vs. not, OR=4.74 (CI 1.94,
11.55)
- Medicate + supplement vs. not,
OR=0.88 (CI 0.57, 1.37)
- Medicare + FFS vs. not,
OR=0.35 (CI 0.16, 0.78)
- Medicare + HMO vs. not,
OR=0.75 (CI 0.26, 2.13)
- Medicare + PPO vs. not,
OR=0.33 (CI 0.14, 0.77)

Estimates were adjusted for
education level, risk category, age
at dx, income, relationship status,
race/ethnicity, and yr of dx. No
estimates or p-values were
reported for these variables.

C-127